Safety, tolerability, and pharmacokinetic characteristics of single and multiple dose escalation of BM219 in healthy subjects, as well as its efficacy and safety in COVID-19 patients: Phase I/II clinical study
Latest Information Update: 05 Feb 2025
Price :
$35 *
At a glance
- Drugs BM-219 (Primary)
- Indications COVID 2019 infections
- Focus Adverse reactions
- Sponsors Biomissile
- 04 Feb 2025 New trial record
- 18 Dec 2024 Status changed from recruiting to completed.